Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial

Annals of Oncology

Volumn 15, Issue 5, 2004, Pages 743-750

  Tripathy, Debu ^a   Lichinitzer, M ^b   Lazarev, A ^c   MacLachlan, S A ^d   Apffelstaedt, J ^e   Budde, M ^f   Bergstrom, B ^f   Abdi, E ^g   Abramson, N ^h   Baker, T M ⁱ   Kirkegaard, L W ⁱ   Schmidt, J R ⁱ   Bell, D ^j   Bell, R ^k   Belt, R J ^l   Bernstein, J I ^m   Just, R G ^m   Burningham, R A ⁿ   Trafficante, B ⁿ   Caggiano, V ^o   Cartwright, T ^p   Chernozemsky, I N ^q   Clingan, P ^r   Conkling, P ^s   Craig, J B ^t   Grosbach, A B ^t   Decker, D ^u   Dickman, E ^v   Dugan Jr , W ^w   Dunlap, W ^x   Eisenberg, P D ^y   Ellerton, J ^z   Ettinger, M ^aa   Ey, F ^ab   Falkson, G ^ac   Falkson, C ^ac   Fink, K ^ad   Fleagle, J ^ae   Forlenza, T ^af   Gorbunova, V A ^b   Gross, G E ^ag   Grotes, T ^ah   Grygiel, J ^ai   Gudgeon, A ^aj   Werner, I D ^aj   Hacking, D ^ak   Harrer, G W ^z   Harvey, V ^al   Hirsch, R ^am   Koletsky, A ^am   Jordaan, J P ^an   Cash, D Kaye ^ao   Khasanov, R Sh ^ap   LaFata, J A ^aq   LaFollette, S ^ar   Koshla, P ^ar   Landers, G ^as   Lebos, H C ^at   Wade, J Lloyd ^au   Lowenthal, T ^av   Lyons, R ^aw   McLachlan, S A ^d   Murray, R ^ax   Perez, D ^ay   Phadke, K ^az   Rapoport, B ^ba   Rausch, P G ^bb   Robinson, B ^bc   Sarna, G ^bd   Saven, A ^be   Schwartz, M ^bf   Semiglazov, V F ^bg   Stewart, J ^bh   Sunderland, K ^bi   Thomas, L ^z   Vogel, C L ^z   Martinez Rio, M ^z   Vorobiof, D A ^bj   Wilks, S ^bk   Woolley, P ^bl   more..

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b Cancer Research Center   (Russian Federation)

^c Oncological Center   (Russian Federation)

^d ST VINCENT S HOSPITAL   (Australia)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g Bendigo Hospital   (Australia)

^h BAPTIST MEDICAL CENTER   (United States)

ⁱ Puget Sound Spine Institute   (United States)

^j ROYAL NORTH SHORE HOSPITAL   (Australia)

^k GEELONG HOSPITAL   (Australia)

^l KS City Oncol/Hematol Clin Bus   (United States)

^m SCRIPPS MEMORIAL HOSPITAL   (United States)

ⁿ Portland Clinic   (United States)

^o Sutter Medical Center   (United States)

^p Ocala Oncology Center   (United States)

^q National Oncology Center Bulgaria   (Bulgaria)

^r WOLLONGONG HOSPITAL   (Australia)

^s SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^t CHRISTUS Schumpert St Mary Place   (United States)

^u WILLIAM BEAUMONT HOSPITAL   (United States)

^v LERNER RESEARCH INSTITUTE   (United States)

^w Pain Center   (United States)

^x Raleigh Medical Group   (United States)

^y Marin General Hospital   (United States)

^z SW Nevada Cancer Res Foundation ^*  (United States)

^aa Clin Res Center of South Florida   (United States)

^ab LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^ac UNIVERSITY OF PRETORIA   (South Africa)

^ad EISENHOWER ARMY MEDICAL CENTER   (United States)

^ae Boulder Medical Center   (United States)

^af ST VINCENT S HOSPITAL   (United States)

^ag EAST TEXAS MEDICAL CENTER   (United States)

^ah FORSYTH MEDICAL CENTER   (United States)

^ai ST VINCENT S HOSPITAL   (Australia)

^aj UNIVERSITY OF CAPE TOWN   (South Africa)

^ak Durban Oncology Centre   (South Africa)

^al AUCKLAND CITY HOSPITAL   (New Zealand)

^am Great Falls Clinic ^*  (United States)

^an ADDINGTON HOSPITAL   (South Africa)

^ao Department of Ophthalmology   (United States)

^ap Russian Federation   (Russian Federation)

^aq North County Internal Medicine   (United States)

^ar RUSH UNIVERSITY MEDICAL CENTER   (United States)

^as Parklands Hospital   (South Africa)

^at MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^au Decatur Meomorial Hospital   (United States)

^av ROYAL HOBART HOSPITAL   (Australia)

^aw Hematol Oncol Assoc of S Texas   (United States)

^ax PETER MACCALLUM CANCER CENTRE   (Australia)

^ay DUNEDIN HOSPITAL   (New Zealand)

^az ST GEORGE HOSPITAL   (Australia)

^ba Medical Oncology Centre of Rosebank   (South Africa)

^bb Frederick Memorial Hospital   (United States)

^bc CHRISTCHURCH HOSPITAL   (New Zealand)

^bd CEDARS SINAI MEDICAL CENTER   (United States)

^be SCRIPPS CLINIC   (United States)

^bf MOUNT SINAI MEDICAL CENTER   (United States)

^bg N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^bh NEWCASTLE MATER HOSPITAL   (Australia)

^bi CANBERRA HOSPITAL   (Australia)

^bj Sandton Oncology Centre   (South Africa)

^bk WILFORD HALL MEDICAL CENTER   (United States)

^bl UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOTOXIC AGENT; IBANDRONIC ACID; NARCOTIC ANALGESIC AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ESOPHAGITIS; EUROPEAN UNION; FEMALE; FLATULENCE; FRACTURE; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; PATHOLOGIC FRACTURE; POISSON DISTRIBUTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; UREMIA; VERTEBRA FRACTURE;

EID: 2642518197     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh173     Document Type: Article

References (37)

1. Greenlee RT, Hill-Hannon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
2. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute 2003; http://seer.cancer.gov/csr/1975_2000
3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-66.
4. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78: 157-169.
5. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378-1391.
6. Lipton A. Bone metastases in breast cancer. Curr Treat Options Oncol 2003; 4: 151-158.
7. Pavlakis N, Stockler M. Bisphosphonates in breast cancer (Cochrane Review). The Cochrane Library 2002.
8. Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19: 3383-3392.
9. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044.
10. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer 2001; 7: 377-387.
11. Saad F, Gleason DM, Murray R et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
12. Body JJ. Bone metastases. In Klastersky J, Schimpff SC, Senn HJ (eds): Handbook of Supportive Care in Cancer, 2nd edition. New York, USA: Marcel Dekker 1999; 453-481.
13. Mian M, Beghe F, Caprio A et al. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res 1991; 11: 107-114.
14. Hurst M, Noble S. Clodronate. A review of its use in breast cancer. Drugs Aging 1999; 15: 143-167.
15. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246: 67-74.
16. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001; 28 (Suppl 11): 49-53.
17. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-3224.
18. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751.
19. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427-2430.
20. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
21. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-405.
22. McCloskey EV, Spector TD, Eyres KS et al. The assessment of vertebrate deformity: a method for use in population studies and clinical trials. Osteoporosis Int 1993; 3: 138-147.
23. Scott M et al. Morbidity measures in the presence of recurrent composite endpoints. Pharmaceutical Statistics 2003; 2: 39-49.
24. Tripathy D, Body J-J, Diel IJ, Bergstrom B. Intravenous and oral ibandronate alleviates pain in patients with skeletal metastases from breast cancer. Breast Cancer Res Treat 2003; 82 (Suppl 1): S69.
25. McCullagh P, Nelder JA. Generalized Linear Models, 2nd edition. New York, NY: Chapman and Hall 1989.
26. Coleman RE. Assessment of response to treatment. In Rubens RD, Forgelman I (eds): Bone Metastases: Diagnosis and Treatment. New York, NY: Springer 1991; 99-120.
27. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954; 41: 133-145.
28. Terpstra TJ. The asymptotic normality and consistency of Kendall's s test against trend, when ties are present in one ranking. Indag Math 1952; 14: 327-333.
29. Coleman RE, Rosen LS, Gordon D et al. Zoledronic acid (4 mg) significantly reduces the relative risk of developing skeletal-related events compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. Breast Cancer Res Treat 2002; 76 (Suppl 1): S95 (Abstr 355).
30. Ernst DS, Brasher P, Hagen N et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997; 13: 319-326.
31. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001; 61: 1253-1274.
32. Aredia: FDA Medical Review: CDER, Application number: 020927, 020036/S015/S016. Posted 19 July 2000 (22 September 1998 approval).
33. Tripathy D, Body JJ, Diel I, Bergstrom B. Oral daily ibandronate: efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer. The Bondronat Study Group. Proc Am Soc Clin Oncol 2003; 22: 46 (Abstr 185).
34. Body JJ, Kanis J, Diel I, Bergstrom B. Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and intravenous ibandronate. The Bondronat Study Group. Proc Am Soc Clin Oncol 2003; 22: 46 (Abstr 184).
35. Coleman RE, Purohit OP, Black C et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311-316.
36. Hilner BE. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol 2001; 28: 64-68.
37. DesHarnais Castel L, Bajwa K, Markle JP et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9: 545-551.